NCT04941898View on ClinicalTrials.gov

A Study of TAK-660 in Surgical Procedures for People With Hemophilia A.

CompletedOBSERVATIONAL

Enrollment

16

Participants

Timeline

Start Date

June 30, 2021

Primary Completion Date

March 15, 2024

Study Completion Date

March 15, 2024

Conditions

Hemophilia A

Interventions

BIOLOGICAL

PEGylated Recombinant Factor VIII

Polyethylene glycol (PEG)-ylated full-length recombinant FVIII (rFVIII)

Trial Locations (1)

Unknown

Takeda Selected Site, Tokyo

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Takeda

INDUSTRY